| Literature DB >> 29321591 |
Harendra Singh Chahar1, Tiziana Corsello1, Andrzej S Kudlicki2, Narayana Komaravelli1, Antonella Casola3,4,5.
Abstract
Exosomes are microvesicles known to carry biologically active molecules, including RNA, DNA and proteins. Viral infections can induce profound changes in exosome composition, and exosomes have been implicated in viral transmission and pathogenesis. No information is current available regarding exosome composition and function during infection with Respiratory Syncytial Virus (RSV), the most important cause of lower respiratory tract infections in children. In this study, we characterized exosomes released from RSV-infected lung carcinoma-derived A549 cells. RNA deep sequencing revealed that RSV exosomes contain a diverse range of RNA species like messenger and ribosomal RNA fragments, as well as small noncoding RNAs, in a proportion different from exosomes isolated from mock-infected cells. We observed that both RNA and protein signatures of RSV were present in exosomes, however, they were not able to establish productive infection in uninfected cells. Exosomes isolated from RSV-infected cells were able to activate innate immune response by inducing cytokine and chemokine release from human monocytes and airway epithelial cells. These data suggest that exosomes may play an important role in pathogenesis or protection against disease, therefore understating their role in RSV infection may open new avenues for target identification and development of novel therapeutics.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29321591 PMCID: PMC5762922 DOI: 10.1038/s41598-017-18672-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Diagram of exosome isolation and characterization. Exosomes were isolated using ExoQuick reagent from conditioned cell culture supernatants and subjected to CD63 immuno-magnetic selection for recovery of highly pure exosomes. Immuno-purified exosomes were then characterized by western blot, using an exosome marker antibody array, and by nanoparticle tracking analysis.
Figure 2Characterization of purified exosomes. (a) Characterization of equal amounts of purified exosomes by protein marker antibody array. The exosome marker array detects 8 known exosome markers namely – CD63, Immunoglobulin superfamily, member 8 (CD81), Programmed cell death 6 interacting protein (ALIX), Flotillin 1 (FLOT1), Intercellular adhesion molecule 1 (ICAM1), Epithelial cell adhesion molecule (EpCam), Annexin A5 (ANXA5) and Tumor susceptibility gene 101 (TSG101). Cis-Golgi matrix protein marker GM130 serves as control to monitor cellular contamination in exosome preparations. PC stands for positive control. (b) Western blot of equal amounts of CD63-purified exosomes using the exosome markers ALIX and CD63. (c) Absolute size determination and quantification of RSV exosomes either reagent enriched or CD63-purified by NanoSight LM10 analysis. The particles were tracked and sized based on Brownian motion and the diffusion coefficient. The mean and mode diameter of exosomes particles are shown. The absolute count of exosome particles was determined and expressed as particles/ml. (d) Exosomes were enriched from 24 h cell supernatants and equal volumes were analyzed for CD63 expression by Western blot assay. Right panel represents densitometric analysis of three independent experiments. ‘*’ Indicates a statistically significant difference (P value < 0.05) comparing RSV exosomes versus mock.
Figure 3RSV viral RNA and protein content in exosomes. (a) Western blot of protein lysates of exosomes using a polyclonal antibody against RSV. (b) RSV N, M and NS1 gene amplification by RT-PCR from CD63-purified exosome RNA. (c) qRT-PCR amplification of genomic and antigenomic RNA present in RSV exosomes.
Figure 4Exosome RNA cargo length profile. (a) Electropherograms and (b) gel images of RNA extracted from exosomes untreated or treated with RNase A in the presence or absence of Triton X-100 and run on the Agilent Bioanalyzer to determine size of RNA fragments.
Figure 5Next generation high-throughput RNA sequencing analysis pipeline flowchart. The flowchart demonstrates how the next generation sequencing data was analyzed. In brief, raw sequencing reads were quality checked for sequencing errors and contaminants using FastQC. Adapter sequences, primers, Ns, and reads with quality score below 28 were trimmed using fastq-mcf of ea-utils and PRINSEQ. Reads < 16 bp after trimming were discarded. Pseudo single-end reads were mapped to the human genome using bowtie. Raw read counts were calculated for known gene categories including ncRNAs, antisense transcripts, coding and intronic regions of mRNAs, and repeats. Annotations of known genes were retrieved from miRBase release 20, NCBI RefSeq, Human lincRNA Catalog, and UCSC Genome Browser. hRSV- Human Respiratory Syncytial Virus, miRNA- microRNA, piRNA- piwi interacting RNA, tRNA- transfer RNA, snRNA- small nucleolar RNA, mRNA-messenger RNA, sncRNA-small noncoding RNA, lincRNA- long intergenic noncoding RNA.
Percentage of RNA types in exosomes derived from mock- and RSV-infected A549 cells derived by dividing the RNA type specific reads by total number of mapped reads.
| RNA type | Percentage in Mock Exosomes | Percentage in RSV Exosomes |
|---|---|---|
| Antisense to exons | 1.7 | 0.3 |
| Antisense to introns | 18.6 | 10.8 |
| Antisense to ncRNAs | 3.4 | 2.1 |
| Antisense to repeat elements | 23.1 | 10.8 |
| CDBox | 0.003 | 0.05 |
| HAcaBox | 0 | 0.006 |
| lincRNA | 0.155 | 0.043 |
| LINE | 4.2 | 0.4 |
| LTR | 2.4 | 0.1 |
| miRNA | 0.04 | 0.3 |
| Other Rfam ncRNA | 0.4 | 5.7 |
| piRNA | 0.1 | 0.8 |
| RefSeq exons | 1.8 | 0.2 |
| RefSeq introns | 16.5 | 9.7 |
| RefSeq lncRNA | 0.5 | 14.2 |
| rRNA | 0.9 | 24.1 |
| scaRNA | 0 | 0.002 |
| SINE | 10.1 | 18.4 |
| Tandem repeat | 0 | 0 |
| tRNA | 1.3 | 0.7 |
| tRNA_like | 1.1 | 0.4 |
| Unannotated | 13.8 | 1.0 |
Figure 6Graphic representation of the relative abundance of small ncRNAs from exosomes.
Top 20 miRNAs upregulated (≥4 fold) and 10 miRNAs downregulated (≥2 fold) in RSV exosomes.
| S. No. | miRNA | Read Count (Avg) | Log2 Fold | |
|---|---|---|---|---|
| Mock Exo | RSV Exo | Change | ||
| 1 | hsa-mir-6087 | 45.59 | 39800.59 | 9.769 |
| 2 | hsa-let-7e | 0.62 | 468.17 | 9.565 |
| 3 | hsa-miR-182-5p | 0.25 | 43.34 | 7.433 |
| 4 | hsa-miR-181b-5p | 0.62 | 77.21 | 6.965 |
| 5 | hsa-mir-128-1 | 0.25 | 14.68 | 5.872 |
| 6 | hsa-miR-19b-3p | 0.25 | 13.24 | 5.722 |
| 7 | hsa-mir-23b | 1.14 | 54.52 | 5.585 |
| 8 | hsa-let-7i | 12.76 | 610.07 | 5.578 |
| 9 | hsa-mir-22 | 2 | 79.13 | 5.303 |
| 10 | hsa-miR-24-3p | 5.98 | 229.59 | 5.263 |
| 11 | hsa-mir-182 | 1.39 | 45.8 | 5.046 |
| 12 | hsa-mir-378a | 0.87 | 28.12 | 5.017 |
| 13 | hsa-mir-99b | 1.14 | 35.93 | 4.983 |
| 14 | hsa-miR-320b | 2.62 | 74.63 | 4.831 |
| 15 | hsa-let-7f-1 | 22.5 | 590.86 | 4.714 |
| 16 | hsa-miR-4516 | 2.97 | 77.27 | 4.700 |
| 17 | hsa-mir-21 | 121.4 | 3155.14 | 4.699 |
| 18 | hsa-mir-30c-2 | 2.1 | 42.72 | 4.343 |
| 19 | hsa-miR-423-5p | 2.24 | 44.06 | 4.298 |
| 20 | hsa-miR-320c | 1.75 | 34.03 | 4.278 |
| 21 | hsa-mir-223 | 21 | 0.17 | −6.911 |
| 22 | hsa-mir-2964a | 62.14 | 0.57 | −6.767 |
| 23 | hsa-mir-205 | 18.17 | 0.29 | −5.993 |
| 24 | hsa-mir-143 | 65.39 | 1.41 | −5.532 |
| 25 | hsa-miR-3168 | 222.71 | 4.82 | −5.530 |
| 26 | hsa-miR-146a-5p | 15.8 | 0.46 | −5.102 |
| 27 | hsa-miR-10b-5p | 56.07 | 4 | −3.809 |
| 28 | hsa-mir-328 | 21.77 | 1.83 | −3.575 |
| 29 | hsa-miR-1246 | 237.74 | 23.03 | −3.367 |
| 30 | hsa-miR-185-5p | 17.3 | 6.91 | −1.324 |
miRNAs detected either in RSV-exosomes or mock-exosomes.
| S. No. | miRNA | Read Count (Avg) | |
|---|---|---|---|
| Mock Exo | RSV Exo | ||
| 1 | hsa-mir-31 | 0 | 529.15 |
| 2 | hsa-mir-3687 | 0 | 114.57 |
| 3 | hsa-mir-222 | 0 | 80.93 |
| 4 | hsa-mir-151a | 0 | 66.10 |
| 5 | hsa-miR-4449 | 0 | 65.29 |
| 6 | hsa-mir-663a | 0 | 56.03 |
| 7 | hsa-mir-196a-2 | 0 | 53.41 |
| 8 | hsa-mir-4508 | 0 | 37.12 |
| 9 | hsa-mir-1248 | 0 | 34.64 |
| 10 | hsa-miR-4497 | 0 | 28.19 |
| 11 | hsa-mir-1273f | 0 | 28.08 |
| 12 | hsa-mir-28 | 0 | 26.67 |
| 13 | hsa-mir-191 | 0 | 20.44 |
| 14 | hsa-miR-3648 | 0 | 17.54 |
| 15 | hsa-miR-194-5p | 0 | 17.14 |
| 16 | hsa-miR-128 | 0 | 14.30 |
| 17 | hsa-mir-1307 | 0 | 13.91 |
| 18 | hsa-mir-744 | 0 | 13.07 |
| 19 | hsa-miR-148b-3p | 0 | 12.31 |
| 20 | hsa-miR-1307-3p | 0 | 12.02 |
| 21 | hsa-mir-663b | 0 | 11.33 |
| 22 | hsa-miR-152 | 0 | 11.19 |
| 23 | hsa-mir-421 | 0 | 10.99 |
| 24 | hsa-mir-7-1 | 0 | 10.43 |
| 25 | hsa-mir-486 | 0 | 10.26 |
| 26 | hsa-miR-1321 | 50.50 | 0 |
| 27 | hsa-mir-204 | 34.07 | 0 |
| 28 | hsa-mir-637 | 22.18 | 0 |
| 29 | hsa-mir-4689 | 19.39 | 0 |
| 30 | hsa-mir-144 | 15.38 | 0 |
| 31 | hsa-miR-4269 | 11.12 | 0 |
| 32 | hsa-mir-885 | 10.50 | 0 |
| 33 | hsa-mir-4795 | 10.50 | 0 |
| 34 | hsa-mir-718 | 10.29 | 0 |
Top biological processes from potential miRNA targets of Tables 2 and 3.
| Table 2 | Table 3 |
|---|---|
| GO:0045944~positive regulation of transcription from RNA polymerase II promoter | GO:0045893~positive regulation of transcription |
| GO:0000122~negative regulation of transcription from RNA polymerase II promoter | GO:0045944~positive regulation of transcription from RNA polymerase II promoter |
| GO:0006351~transcription | GO:0000122~negative regulation of transcription from RNA polymerase II promoter |
| GO:0045893~positive regulation of transcription | GO:0006366~transcription from RNA polymerase II promoter |
| GO:0045892~negative regulation of transcription | GO:0006351~transcription |
| GO:0006468~protein phosphorylation | GO:0045892~negative regulation of transcription |
| GO:0006366~transcription from RNA polymerase II promoter | GO:0006468~protein phosphorylation |
| GO:0023014~signal transduction by protein phosphorylation | GO:0042472~inner ear morphogenesis |
| GO:0006355~regulation of transcription | GO:0007507~heart development |
| GO:0016569~covalent chromatin modification | GO:0048015~phosphatidylinositol-mediated signaling |
| GO:1900740~positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway | GO:0007173~epidermal growth factor receptor signaling pathway |
| GO:0048015~phosphatidylinositol-mediated signaling | GO:0035335~peptidyl-tyrosine dephosphorylation |
| GO:0006915~apoptotic process | GO:0030097~hemopoiesis |
| GO:0009952~anterior/posterior pattern specification | GO:0001525~angiogenesis |
| GO:0043525~positive regulation of neuron apoptotic process | GO:0031175~neuron projection development |
| GO:0060021~palate development | GO:0018105~peptidyl-serine phosphorylation |
| GO:0016055~Wnt signaling pathway | GO:0006607~NLS-bearing protein import into nucleus |
| GO:0010468~regulation of gene expression | GO:0009952~anterior/posterior pattern specification |
| GO:0035278~miRNA mediated inhibition of translation | GO:0035194~posttranscriptional gene silencing by RNA |
| GO:0035194~posttranscriptional gene silencing by RNA | GO:0007165~signal transduction |
Top molecular functions from potential miRNA targets of Tables 2 and 3.
| Table 2 | Table 3 |
| GO:0005515~protein binding | GO:0005515~protein binding |
| GO:0003700~transcription factor activity | GO:0003700~transcription factor activity |
| GO:0003677~DNA binding | GO:0043565~sequence-specific DNA binding |
| GO:0008134~transcription factor binding | GO:0001077~transcriptional activator activity |
| GO:0001077~transcriptional activator activity | GO:0004672~protein kinase activity |
| GO:0004674~protein serine/threonine kinase activity | GO:0004674~protein serine/threonine kinase activity |
| GO:0046332~SMAD binding | GO:0044212~transcription regulatory region DNA binding |
| GO:0046872~metal ion binding | GO:0008270~zinc ion binding |
| GO:0008270~zinc ion binding | GO:0008134~transcription factor binding |
| GO:0043565~sequence-specific DNA binding | GO:0004702~receptor signaling protein serine/threonine kinase activity |
| GO:0003730~mRNA 3′-UTR binding | GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding |
| GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding | GO:0003714~transcription corepressor activity |
| GO:0004702~receptor signaling protein serine/threonine kinase activity | GO:0004725~protein tyrosine phosphatase activity |
| GO:0003682~chromatin binding | GO:0042826~histone deacetylase binding |
| GO:0004842~ubiquitin-protein transferase activity | GO:0008013~beta-catenin binding |
| GO:0044325~ion channel binding | GO:0019838~growth factor binding |
| GO:0003714~transcription corepressor activity | GO:0003682~chromatin binding |
| GO:0005524~ATP binding | GO:0003677~DNA binding |
| GO:0044212~transcription regulatory region DNA binding | GO:0005524~ATP binding |
| GO:0004843~thiol-dependent ubiquitin-specific protease activity | GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding |
Figure 7Validation of miRNA expression in cells and exosomes. RNA extracted from A549 cells (a) or SAE cells (b) mock- and RSV-infected for 24 h (left panels) and from mock and RSV exosomes (right panels) was subjected to miRNA analysis by RT-PCR. Fold changes in miRNA expression were determined by the 2-ΔΔCt method and represent mean ± SD normalized to small-nucleolar RNA U6 (RNU6).
Top 15 highly up and downregulated piRNAs (≥4 fold) in RSV exosomes.
| S. No. | piRNA | Read Count (Avg) | Log2 Fold | |
|---|---|---|---|---|
| Mock Exo | RSV Exo | Change | ||
| 1 | piR-32678 | 127.41 | 27150.88 | 7.735 |
| 2 | piR-31623 | 0.62 | 48.19 | 6.285 |
| 3 | piR-34736 | 1.74 | 128.93 | 6.21 |
| 4 | piR-36169 | 6.52 | 231.03 | 5.147 |
| 5 | piR-36170 | 6.52 | 231.03 | 5.147 |
| 6 | piR-49143 | 22.5 | 590.86 | 4.714 |
| 7 | piR-33748 | 7.13 | 108.2 | 3.922 |
| 8 | piR-45371 | 7.13 | 108.2 | 3.922 |
| 9 | piR-49144 | 126.89 | 1387.4 | 3.450 |
| 10 | piR-33043 | 33.7 | 291.08 | 3.110 |
| 11 | piR-33044 | 33.7 | 291.08 | 3.110 |
| 12 | piR-34531 | 5.88 | 24.21 | 2.041 |
| 13 | piR-34532 | 5.88 | 24.21 | 2.041 |
| 14 | piR-34533 | 5.88 | 24.21 | 2.041 |
| 15 | piR-34534 | 5.88 | 24.21 | 2.041 |
| 16 | piR-59169 | 1364.92 | 6.02 | −7.824 |
| 17 | piR-50653 | 22.7 | 0.13 | −7.473 |
| 18 | piR-50654 | 22.7 | 0.13 | −7.473 |
| 19 | piR-50655 | 22.7 | 0.13 | −7.473 |
| 20 | piR-55865 | 22.7 | 0.13 | −7.473 |
| 21 | piR-56226 | 22.7 | 0.13 | −7.473 |
| 22 | piR-34756 | 10411.18 | 82.62 | −6.977 |
| 23 | piR-34370 | 28.39 | 0.29 | −6.637 |
| 24 | piR-45065 | 21.57 | 0.29 | −6.241 |
| 25 | piR-40249 | 50.07 | 0.74 | −6.070 |
| 26 | piR-40514 | 59.65 | 1.03 | −5.855 |
| 27 | piR-36037 | 85.04 | 1.78 | −5.578 |
| 28 | piR-34916 | 29.19 | 0.63 | −5.524 |
| 29 | piR-56647 | 40.04 | 1.03 | −5.280 |
| 30 | piR-59089 | 10.75 | 0.29 | −5.236 |
piRNAs detected either in RSV-exosomes or mock-exosomes.
| S. No. | piRNA | Read Count (Avg) | |
|---|---|---|---|
| Mock Exo | RSV Exo | ||
| 1 | piR-31703 | 0 | 254.19 |
| 2 | piR-33650 | 0 | 209.91 |
| 3 | piR-40982 | 0 | 209.39 |
| 4 | piR-32079 | 0 | 209.21 |
| 5 | piR-31961 | 0 | 208.91 |
| 6 | piR-33527 | 0 | 153.92 |
| 7 | piR-33526 | 0 | 153.02 |
| 8 | piR-36716 | 0 | 127.96 |
| 9 | piR-36715 | 0 | 127.67 |
| 10 | piR-36714 | 0 | 127.39 |
| 11 | piR-36494 | 0 | 127.01 |
| 12 | piR-36713 | 0 | 125.77 |
| 13 | piR-35059 | 0 | 124.97 |
| 14 | piR-34608 | 0 | 118.37 |
| 15 | piR-48517 | 0 | 118.37 |
| 16 | piR-60668 | 0 | 58.07 |
| 17 | piR-61919 | 0 | 46.01 |
| 18 | piR-31701 | 0 | 36.7 |
| 19 | piR-34221 | 0 | 21.87 |
| 20 | piR-61950 | 19.15 | 0 |
| 21 | piR-59554 | 13.59 | 0 |
| 22 | piR-61974 | 11.12 | 0 |
Figure 8Proinflammatory mediator secretion by monocytes and A549 cells in response to exosome stimulation. Human monocytes were stimulated with mock or RSV exosomes and harvested 24 h later to collect cell supernatants to measure cytokine and chemokine secretion by cytokine multiplex assay (a) or ELISA (b). Similar experiment was performed in A549 cells (c). Data are expressed as mean ± SEM, and ‘*’ indicates a statistically significant difference (P value < 0.05).